Lupin announced that the US Court has lifted the Temporary Restraining Order and denied Astellas' request for a preliminary injunction on Mirabegron ER Tablets. Thereafter, shipment of the
product has now resumed.
Mirabegron ER Tablets, 25 mg are a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc., and were launched by Lupin in April 2024.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
